Journal article
Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections including Impetigo, Cellulitis, and Abscess
AC Bowen, JR Carapetis, BJ Currie, V Fowler, HF Chambers, SYC Tong
Open Forum Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2017
DOI: 10.1093/ofid/ofx232
Abstract
Skin and soft tissue infections (SSTI) affect millions of people globally, which represents a significant burden on ambulatory care and hospital settings. The role of sulfamethoxazole-trimethoprim (SXT) in SSTI treatment, particularly when group A Streptococcus (GAS) is involved, is controversial. We conducted a systematic review of clinical trials and observational studies that address the utility of SXT for SSTI treatment, caused by either GAS or Staphylococcus aureus, including methicillin-resistant (MRSA). We identified 196 studies, and 15 underwent full text review by 2 reviewers. Observational studies, which mainly focused on SSTI due to S aureus, supported the use of SXT when compared..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
A.C.B. is the recipient of an Australian National Health and Medical Research Council (NHMRC) early career fellowship scholarship (1088735). S.Y.C.T. is the recipient of an NHMRC Career Development Fellowship (1065736). This work is supported by NHMRC project grant 1131932 (the HOT NORTH initiative).